Dukes Prevents Class Cert. In Nexium MDL, AstraZeneca Says
AstraZeneca PLC and several generic-drug makers facing multidistrict antitrust litigation alleging they unlawfully delayed the market entry of a generic form of Nexium told a Massachusetts federal judge Monday that a...To view the full article, register now.
Already a subscriber? Click here to view full article